We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immune Responses Evaluated for Tick-Borne Encephalitis

By LabMedica International staff writers
Posted on 13 May 2020
Print article
Image: The Simultest IMK-Lymphocyte is a two-color direct immunofluorescence reagent kit for enumerating percentages of the following mature human leucocyte subsets in erythrocyte-lysed whole blood (Photo courtesy of BDBiosciences).
Image: The Simultest IMK-Lymphocyte is a two-color direct immunofluorescence reagent kit for enumerating percentages of the following mature human leucocyte subsets in erythrocyte-lysed whole blood (Photo courtesy of BDBiosciences).
Tick-borne encephalitis (TBE) is an important vector-borne infection of the central nervous system (CNS). The majority of all reported cases of TBE occur in adults. However, TBE should also be included in the differential diagnosis of pediatric CNS infections in endemic areas.

The chemokine CXCL13 is one of the key determinants of the humoral immune response at the site of an infection. CXCL13 is expressed in lymphoid organs and controls the recruitment and compartmentalization of B-cells and CD4+ T lymphocytes within these structures. CXCL13 is produced by microglia, stromal cells in the meninges, and infiltrating lymphoid cells.

Infectious disease specialists at the Medical University of Bialystok (Bialystok, Poland) analyzed anti-tick-borne encephalitis virus (TBEV) antibody levels, cerebrospinal fluid (CSF) and blood lymphoid populations, and concentrations of CXCL13 (a potent B-cell and T-cell chemoattractant), in 35 patients with TBE (20 adults and 15 children). TBE was defined as a febrile illness with signs of meningitis or meningoencephalitis, a CSF cell count of more than 5 cells/μL, and the presence of serum IgM and IgG antibodies to TBEV.

The detection of anti-TBEV IgG and IgM antibodies in serum and CSF was performed by enzyme-linked immunosorbent assay (ELISA), using SERION ELISA classic kits (Würzburg, Germany). The CXCL13 concentration quotient was calculated as QCXCL13 = CXCL13CSF/CXCL13serum. QCXCL13 was used as a measure of the chemical gradient of that chemokine. A value greater than 1 indicates a higher concentration of CXCL13 in the CSF than in the serum. All serum and CSF samples were stored at −80 °C until analysis of the chemokine. For flow cytometry, samples were analyzed within 18 hours on a FACSCanto II cytometer (BDBiosciences, San Jose, CA, USA). The Simultest IMK-Lymphocyte kit from BD Biosciences was used to study peripheral blood and CSF lymphocyte fractions

The scientists reported that when compared with the blood, the CSF lymphoid population was significantly enriched in CD4+ T-cells and relatively depleted in natural killer (NK) cells and B lymphocytes. In comparison with TBE meningitis, patients suffering from TBE meningoencephalitis (11, 31%) had a 3.5-fold higher median CSF CXCL13 concentration, 1.8-fold higher CSF/serum ratio of anti-TBEV IgG antibodies, and 1.8-fold higher median CSF cell count. CSF CXCL13 levels did not change significantly in children with TBE meningitis receiving supportive treatment, but decreased in children with TBE meningoencephalitis who received intravenous steroids.

The authors concluded that the CSF in patients with TBE was abundant in CD4+ cells and relatively depleted in NK cells and in B lymphocytes, when compared with the blood. A higher absolute number of lymphocytes in the CSF were associated with a more severe course of TBE. CXCL13 may be involved in the neuropathology of TBE by attracting different subsets of lymphocytes into the CSF, but it remains unclear whether this chemokine contributes directly to disease severity. The study was published on April 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Medical University of Bialystok
SERION
BDBiosciences


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.